

From Airway to Axon: Repurposing Ambroxol as a Nav1.8-Preferring Blocker for Chronic Neuropathic Pain

Milap Joshi DO[1], Daniel Pan MD[2], Patricia Moesner MD[1]
[1]Department of Physical Medicine & Rehabilitation, Corewell Health East
[2]Department of Physical Medicine & Rehabilitation, University of Michigan

Corewell Health™

THE PROBLEM

- Chronic neuropathic pain affects **7–10% of adults**
- **Fewer than half** of patients reach meaningful relief on first-line systemic agents
- Centrally acting agents can cause sedation, cognitive slowing, and other dose-limiting CNS effects

THE TARGET

Nav1.8 (SCN10A) is a voltage-gated sodium channel expressed in peripheral nociceptors and a **validated non-opioid analgesic target.**

Blocking it at the nerve terminal should quiet pain signaling without touching the brain.

THE CANDIDATE

Ambroxol, an inexpensive oral mucolytic used for airway disease, blocks Nav1.8 in a **use-dependent** manner. Applied topically, it concentrates where nociceptors are localized, and has minimal penetration into the CNS.

HOW WE LOOKED

- Narrative review of **PubMed** and **ClinicalTrials.gov** through **July 2026**
- **Topical administration only,** oral ambroxol data was excluded
- Extracted: sample size, concentration, treatment length, onset and duration of relief, prior failed topical therapy, and adverse events
- Registries queried for completed or ongoing randomized trials


WHAT 20 PATIENTS SHOWED

Topical ambroxol 20% dropped pain by **2–8 points** in as little as **5 minutes** — with **no adverse events** reported!

All 20 patients come from **three uncontrolled case series**. **No randomized trial of topical ambroxol exists.** Efficacy is not established.

Ambroxol blocks the current that keeps neurons firing:

IC_{50} against Nav1.8, μM: lower means more potent



~6× more potent against persistent current

Block is state-dependent: strongest in neurons that are actively firing, and inhibition stays peripheral with minimal CNS involvement.

Patient's response, across three case series:

Filled circles representing improved symptoms

Refractory neuropathic pain
NRS fell 2–8 points · relief 3–8 h
●●●●●●● **7 of 7**

Complex regional pain syndrome
Edema & hyperalgesia improved
●●●●●●●○ **7 of 8**

Trigeminal neuralgia
Fewer attacks · relief 4–6 h
●●●●● **5 of 5**

4 of 7 refractory patients had already failed lidocaine 5%, and **1** failed capsaicin 8%. **2** trigeminal patients reduced oral pain medication. **1** reported resolution.

WHY TOPICAL MAKES SENSE

- **Minimal CNS penetration:** mechanism that typically limits systemic agents at higher doses would not apply to Ambroxol
- Greater potency at **actively firing** channels means the drug works hardest where pain is being generated
- **Reductions met the clinically significant 2-point threshold**
- Relief persisted with continued use with 5 of 7 reported **fewer attacks** over **up to 4 years**

WHAT WE CANNOT SAY


- Evidence is **uncontrolled** and **non-standardized**
- No randomized trial of topical ambroxol was identified
- **Efficacy remains unestablished**

WHAT WOULD SETTLE IT


- A **standardized formulation**
- **Randomized, double-blinded** trials
- Standardized patients with intact, sensitized nociceptors confirmed on **quantitative sensory testing**
- **Structured application-site monitoring**

Scan for full abstract and supplemental information.
Consists of complete abstract and supplemental information with regards to Ambroxol's structural rationale and theoretical analogues.


ABROXOL STRUCTURE & POTENTIAL DERIVATIVES CREATED USING AI




Ambroxol




Analogue 1 — Permanently Charged



Analogue 2 — Halogen Exchange



Analogue 3 — Restricted Linker



Analogue 4 — Ester Prodrug

REFERENCES

1. Gaida W, Klinder K, Arndt K, Weiser T. Ambroxol, a Nav1.8-preferring Na^+ channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. *Neuropharmacology.* 2005;49(8):1220–1227.
2. Hefner S, Oprita G, Pantke S, Hage A, Leffler A. Nav1.8, TRPV1 and TRPA1 as possible targets of ambroxol when used for topical treatment of neuropathic pain. *J Pain.* 2025;37:105563.
3. Kern KU, Weiser T. Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation. *Schmerz.* 2015;29(Suppl 3):S89–S96.
4. Kern KU, Schwickert-Nieswandt M, Maihöfner C, Gaul C. Topical ambroxol 20% for the treatment of classical trigeminal neuralgia — a new option? Initial clinical case observations. *Headache.* 2019;59(3):418–429.
5. Russo MA, Baron R, Dickenson AH, Kern KU, Santarelli DM. Ambroxol for neuropathic pain: hiding in plain sight? *Pain.* 2023;164(1):3–13.